- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics | 4 | CNW | ||
| CONEXEU SCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | Conexeu Sciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Di | Conexeu Sciences Inc.: A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill | 1 | GlobeNewswire (USA) | ||
| 25.06. | Conexeu Sciences Inc.: Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform | 1 | GlobeNewswire (USA) | ||
| 22.06. | Conexeu Sciences stock initiated at buy by H.C. Wainwright, $20 target | 1 | Investing.com | ||
| 15.06. | Conexeu Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.06. | Conexeu Sciences Inc.: Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing | 197 | GlobeNewswire (Europe) | RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced additions to... ► Artikel lesen | |
| 09.06. | Conexeu Sciences Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Conexeu Sciences: Aktie legt nach Fortschritten bei Wundversorgungs-Produkt zu | 1 | Investing.com Deutsch | ||
| 08.06. | Conexeu forciert Produktionsaufbau für Wundpflege-Produkt vor geplantem FDA-Antrag 2027 | - | Investing.com Deutsch | ||
| 08.06. | Conexeu Sciences Inc.: Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU Wound Care Program | 1 | GlobeNewswire (USA) | ||
| 03.06. | Conexeu Sciences Inc.: Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 21.05. | Conexeu Sciences Inc.: Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU" | 493 | Newsfile | Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially... ► Artikel lesen | |
| 19.05. | Conexeu Sciences Inc.: Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants | 460 | Newsfile | Conexeu's B.R.E.A.S.T. was developed using the Company's proprietary CXU regenerative tissue platform to support gradual tissue remodelingDesigned as a resorbable, bioregenerative tissue matrix... ► Artikel lesen | |
| 14.05. | Conexeu Sciences Inc.: Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration | 446 | Newsfile | Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular... ► Artikel lesen | |
| 12.05. | Medical device developer Conexeu Sciences set to direct list on the Nasdaq on May 21 | 1 | Renaissance Capital | ||
| 11.05. | Conexeu Sciences Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 17.04. | Conexeu Sciences Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 06.04. | Conexeu Sciences Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 26.03. | Conexeu Sciences Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO-DIAGNOSTICS | 2,630 | +0,77 % | Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test | More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs
Analytical... ► Artikel lesen | |
| CYTOSORBENTS | 0,294 | -5,77 % | Cytosorbents Corp - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 3,910 | -4,63 % | Clover Health Investments, Corp.: Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| FULGENT GENETICS | 17,900 | -1,10 % | Fulgent reports interim data for cancer drug FID-007 trial | ||
| EMBECTA | 2,790 | +0,40 % | Embecta Corp.: embecta appoints Nimish Muzumdar as SVP and President, North America | PARSIPPANY, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical... ► Artikel lesen | |
| CHECK-CAP | 1,030 | -0,96 % | Check-Cap Ltd - 6-K, Report of foreign issuer | ||
| ELECTROCORE | 5,700 | +3,64 % | electroCore, Inc.: electroCore Announces Full Year 2025 Financial Results and Organizational Changes | Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness... ► Artikel lesen | |
| CATHETER PRECISION | 0,815 | -29,13 % | Catheter Precision Plunges as Traders Unwind Gains from Recent News | ||
| CLEARPOINT NEURO | 17,500 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint | Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including... ► Artikel lesen | |
| ENVUE MEDICAL | 0,528 | 0,00 % | ENvue unveils robotic-assisted AI feeding tube automation tool | ||
| FIREFLY NEUROSCIENCE | 1,155 | +0,43 % | Firefly Neuroscience, Inc.: Firefly Confirms Public-Private Partnership with the Department of War | Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of... ► Artikel lesen | |
| ENDRA LIFE SCIENCES | 5,610 | 0,00 % | ENDRA Life Sciences Inc. - 8-K, Current Report | ||
| FEMASYS | 4,000 | +0,25 % | Femasys Inc.: Femasys Regains Compliance with Nasdaq Listing Requirements | ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective... ► Artikel lesen | |
| CUPRINA HOLDINGS | 4,850 | -8,32 % | Cuprina Holdings LTD - F-1, Registration statement for certain foreign private issuers | ||
| EXAGEN | 3,960 | +5,32 % | Exagen Inc. Reports First Quarter 2026 Results | CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026... ► Artikel lesen |
CONEXEU SCIENCES INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 10,000 Euro und damit -1,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CONEXEU SCIENCES INC finden Sie auf Wallstreet Online.